Publications

1. Fox J, Tiraboschi JM, Herrera C, Else L, Egan D, Dickinson L, Jackson A, Olejniczak N, Back D, Khoo S, Shattock R, Boffito M. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):252-257. PMID: 27727157

2. McGowan I, Dezzutti CS, Siegel A, Engstrom J, Nikiforov A, Duffill K, Shetler C, Richardson-Harman N, Abebe K, Back D, Else L, Egan D, Khoo S, Egan JE, Stall R, Williams PE, Rehman KK, Adler A, Brand RM, Chen B, Achilles S, Cranston RD.. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.. Lancet HIV. 2016 Sep 16. pii: S2352-3018(16)30113-8. doi: 10.1016/S2352-3018(16)30113-8. [Epub ahead of print] PMID: 27658864

3. Olagunju A, Khoo S, Owen A. Pharmacogenetics of nevirapine excretion into breast milk and infants’ exposure through breast milk versus postexposure prophylaxis. Pharmacogenomics 2016 Jun;17(8):891-906. doi: 10.2217/pgs-2015-0016. PMID: 27268507

4. Penchala SD, Fawcett S, Else L, Egan D, Amara A, Elliot E, Challenger E, Back D, Boffito M, Khoo S. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 27;1027:174-180. doi: 10.1016/j.jchromb.2016.05.040. PMID: 27290668

5. Nightingale S, Geretti AM, Beloukas A, Fisher M, Winston A, Else L, Nelson M, Taylor S, Ustianowski A, Ainsworth J, Gilson R, Haddow L, Ong E, Watson V, Leen C, Minton J, Post F, Pirmohamed M, Solomon T, Khoo S. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. J Neurovirol. 2016 May 18. [Epub ahead of print] PMID: 27194435

6. Olagunju A, Bolaji O, Neary M, Back D, Khoo S, Owen A. Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Pharmacogenet Genomics. 2016 May 18. [Epub ahead of print] PMID: 2719552

7. Nightingale S, Chau TT, Fisher M, Nelson M, Winston A, Else L, Carr DF, Taylor S, Ustianowski A, Back D, Pirmohamed M, Solomon T, Farrar J, Törok ME, Khoo S; PARTITION-Vietnam study group. Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis. Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280-16. [Epub ahead of print] PMID: 27161633

8. Nightingale S, Michael BD, Fisher M, Winston A, Nelson M, Taylor S, Ustianowski A, Ainsworth J, Gilson R, Haddow L, Ong E, Leen C, Minton J, Post F, Beloukas A, Borrow R, Pirmohamed M, Geretti AM, Khoo S, Solomon T. CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine. 2016 Apr 28;83:139-146. doi: 10.1016/j.cyto.2016.04.004. [Epub ahead of print] PMID: 27131579

9. Moltó J, Graterol F, Miranda C, Khoo S, Bancu I, Amara A, Bonjoch A, Clotet B. Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother. 2016 Feb 8. pii: AAC.03131-15. PMID: 26856824

10. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet. 2015 Dec 29. PMID: 26715213

11. Dickinson L, Winston A, Boffito M, Khoo S, Back D, Siccardi M. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. J Antimicrob Chemother. 2015 Dec 27. pii: dkv439. PMID: 26712906

12. Elliot E, Amara A, Jackson A, Moyle G, Else L, Khoo S, Back D, Owen A, Boffito M. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. J Antimicrob Chemother. 2015 Dec 17. pii: dkv425. PMID: 26679246

13. Schipani A, Pertinez H, Mlota R, Molyneux E, Lopez N, Dzinjalamala FK, van Oosterhout JJ, Ward SA, Khoo S, Davies G. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. Br J Clin Pharmacol. 2015 Nov 27. doi: 10.1111/bcp.12848. [Epub ahead of print] PMID: 26613187

14. Seng KY, Hee KH, Soon GH, Chew N, Khoo SH, Lee LS. Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. J Antimicrob Chemother. 2015 Sep 4. pii: dkv268. [Epub ahead of print] PMID: 26342028

15. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo S, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): efficacy results from a pragmatic open-label randomised pilot trial. Lancet 2015; Sep 9. pii: S0140-6736(15)00056-2. doi: 10.1016/S0140-6736(15)00056-2. PMID: 26364263

16. Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group. Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul. PMID: 26288843

17. Seng KY, Hee KH, Soon GH, Chew N, Khoo SH, Lee LS. Population Pharmacokinetic Analysis of Isoniazid, Acetyl-isoniazid and Isonicotinic Acid in Healthy Volunteers. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01244-15. [Epub ahead of print] PMID: 26282412

18. Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, Khoo S, Back D, Karolia Z, Higgs C, Boffito M. Plasma Tenofovir, Emtricitabine and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics Following Drug Intake Cessation. Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.01441-15. [Epub ahead of print] PMID: 26195515

19. Olagunju A, Amara A, Waitt C, Else L, Penchala SD, Bolaji O, Soyinka J, Siccardi M, Back D, Owen A, Khoo S. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. J Antimicrob Chemother. 2015 Jun 24. pii: dkv174. [Epub ahead of print] PMID: 26108608

20. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 study group. Pharmacokinetic and Pharmacodynamic Comparison of Once Daily Efavirenz (400mg Versus 600mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther. 2015 Jun 5. doi: 10.1002/cpt.156

21. Olagunju A, Bolaji O, Amara A, Waitt C, Else L, Adejuyigbe E, Siccardi M, Back D, Khoo S, Owen A. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically-defined subgroups of mother-infant pairs: an observational study. Clin Infect Dis. 2015 Apr 16. pii: civ317. [Epub ahead of print] PMID: 25882300

22. Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother. 2015 Apr 8. pii: dkv080. [Epub ahead of print] PMID: 25858354

23. Mora-Peris B, Else L, Goldmeier D, Mears A, Weston R, Cooke G, Khoo S, Back D, Winston A. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. J Antimicrob Chemother. 2015 Feb 17. pii: dkv035. [Epub ahead of print] PMID: 25693997

24. Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, Oyigboja J, Back D, Khoo S, Owen A. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin Pharmacol Ther. 2015 Mar;97(3):298-306. doi: 10.1002/cpt.43. Epub 2015 Jan 20. PMID: 25669165

25. Lamorde M, Walimbwa S, Byakika-Kibwika P, Katwere M, Mukisa L, Sempa JB, Else L, Back DJ, Khoo SH, Merry C. Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother. 2015 Feb 3. pii: dku575. [Epub ahead of print] PMID: 25652748

26. Winston A, Amin J, Clarke A, Else L, Amara A, Barber T, Jessen H, Avinghsanon A, Chetchotisakd P, Khoo S, Cooper DA, Emery S, Puls R; for the ENCORE CSF sub-study team. Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomised controlled trial. Clin Infect Dis. 2015 Apr 1;60(7):1026-32. doi: 10.1093/cid/ciu976 PMID: 25501988

27. S. D. Penchala, J. Tjia, O. El Sherif, D. J. Back, S. H. Khoo, and L. J. Else, 'Validation of an Electrospray Ionisation Lc-Ms/Ms Method for Quantitative Analysis of Telaprevir and Its R-Diastereomer', J Chromatogr B Analyt Technol Biomed Life Sci, 932 (2013), 100-10.

28. B. Mora-Peris, A. Croucher, L. J. Else, J. H. Vera, S. Khoo, G. Scullard, D. Back, and A. Winston, 'Pharmacokinetic Profile and Safety of 150 Mg of Maraviroc Dosed with 800/100 Mg of Darunavir/Ritonavir All Once Daily, with and without Nucleoside Analogues, in Hiv-Infected Subjects', J Antimicrob Chemother, 68 (2013), 1348-53.

29. A. Jackson, A. Hill, R. Puls, L. Else, J. Amin, D. Back, E. Lin, S. Khoo, S. Emery, R. Morley, B. Gazzard, and M. Boffito, 'Pharmacokinetics of Plasma Lopinavir/Ritonavir Following the Administration of 400/100 Mg, 200/150 Mg and 200/50 Mg Twice Daily in Hiv-Negative Volunteers', J Antimicrob Chemother, 66 (2011), 635-40.

30. L. J. Else, A. Jackson, R. Puls, A. Hill, P. Fahey, E. Lin, A. Amara, M. Siccardi, V. Watson, J. Tjia, S. Emery, S. Khoo, D. J. Back, and M. Boffito, 'Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the Encore 2 Study', Antimicrob Agents Chemother, 56 (2012), 1427-33.

31. L. Else, V. Watson, J. Tjia, A. Hughes, M. Siccardi, S. Khoo, and D. Back, 'Validation of a Rapid and Sensitive High-Performance Liquid Chromatography-Tandem Mass Spectrometry (Hplc-Ms/Ms) Assay for the Simultaneous Determination of Existing and New Antiretroviral Compounds', J Chromatogr B Analyt Technol Biomed Life Sci, 878 (2010), 1455-65.

32. David Back, Laura Else, The importance of drug–drug interactions in the DAA era, Digestive and Liver Disease, Volume 45, Supplement 5, 30 September 2013, Pages S343-S348, ISSN 1590-8658.

33. Moyle, G., et al. (2013). "Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics." Antimicrobial Agents and Chemotherapy 57(8): 3640-3644.